Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …

Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …

Abstract Background Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …

Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic
regulation is a heritable change in gene expressions independent of nucleotide sequence …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for
B-cell–driven malignancies. However, approved covalent BTK inhibitors (cBTKis) are …

Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–
modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who …